Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Is metformin associated with acute kidney injury? A case-control study of patients with type 2 diabetes admitted with acute infection

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?

    Research output: Contribution to journalReviewResearchpeer-review

  1. Diabetes increases the risk of bone fractures in patients on kidney replacement therapy: A DANISH national cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clopidogrel, prasugrel, and ticagrelor for all-comers with ST-segment elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Nationwide cardiovascular disease admission rates during a second COVID-19 lockdown

    Research output: Contribution to journalLetterResearchpeer-review

  4. Workforce Attachment after Ischemic Stroke – The Importance of Time to Thrombolytic Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Despite the long-term renoprotective effects of Metformin, a recent study on data from the U.S. Food and Drug Administration reported a possible nephrotoxic effect, contributing to the development of acute kidney injury (AKI). We investigated the association between metformin and AKI in patients admitted with the AKI-prone condition of acute infection and compared results with corresponding results of other antidiabetics.

METHODS: In a nationwide register-based case-control study, we identified Danish patients with type 2 diabetes hospitalized with acute infection between 2008 and 2018. Cases of AKI had an increase in plasma creatinine ≥  × 1.5 during admission, controls did not. Antidiabetics were identified up to 6 months before admission. Odds ratio (OR) of each antidiabetic was computed in separate multiple logistic regression models adjusted for relevant medication and comorbidities and results compared.

RESULTS: We included 46,811 patients, hereof 9454 AKIs (20%) and 2186 (4.7%) severe AKIs. Overall, 56% were males, median age (IQR) was 73 (65-81). Sixty percent received metformin, 13% sulfonylurea, 31% insulin and 8% dipeptidyl peptidase-4 inhibitors (DPP-4i), with equal distribution between cases and controls. Metformin was associated with increased OR (CI) for AKI, 1.07 (1.02-1.12), equally to sulfonylurea, 1.10 (1.03-1.18) and DPP-4i, 1.11 (1.02-1.20), but not insulin, 0.99 (0.93-1.05). In severe AKI, results for metformin were 1.27 (1.25-1.40) but increased equivalently to other antidiabetics.

CONCLUSIONS: In patients with type 2 diabetes hospitalized with acute infection, metformin was not independently associated with AKI, since other antidiabetics were also significantly associated, indicating confounding by indication.

Original languageEnglish
JournalJournal of Nephrology
Volume34
Issue number3
Pages (from-to)709-717
Number of pages9
ISSN1121-8428
DOIs
Publication statusPublished - Jun 2021

    Research areas

  • Acute kidney injury, Diabetes, Hypoglycemic agents, Metformin, Observational study

ID: 60964471